Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511795 · ClinicalTrials.gov registry record · Phase 1
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT02511795 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 128 participants.
The verdict
NCT02511795, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
The purpose of this Phase 1b, multi-centre, dose escalation study is to find the maximum tolerated dose (MTD) of AZD1775 combined with olaparib in patients with refractory solid tumours
Interventions
- DRUG Olaparib
- DRUG AZD1775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2015-08-06 |
| Est. Completion | 2019-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02511795
The ClinicalTrials.gov registry entry for NCT02511795 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT02511795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02511795 about?
NCT02511795 is a clinical study titled "AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors". The purpose of this Phase 1b, multi-centre, dose escalation study is to find the maximum tolerated dose (MTD) of AZD1775 combined with olaparib in patients with refractory solid tumours
What is the current status of trial NCT02511795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2015-08-06. Estimated completion is 2019-10-16.
What interventions are being tested in trial NCT02511795?
The interventions under investigation include: Olaparib (DRUG), AZD1775 (DRUG).
Who is sponsoring clinical trial NCT02511795?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.